Bliss Media

Bliss Biopharmaceutical is a clinical-stage biopharmaceutical company specializing in the development of innovative antibody-drug conjugates (ADCs) for cancer treatment. Based in Hangzhou, China, the company leverages its proprietary linker-payload platforms to create ADCs with enhanced stability and potent anti-tumor activity. Its lead asset, BB-1701, is a HER2-targeting ADC currently undergoing Phase 2 clinical evaluation for breast and lung cancers in collaboration with Eisai. The company's pipeline also features BB-1705 (EGFR-targeted) and BB-1709 (Nectin-4-targeted), both in early clinical stages. Bliss Biopharmaceutical is backed by leading venture capital firms such as Lilly Asia Ventures and Sequoia China, positioning it as a significant player in the global ADC landscape.